Medicines Development for Global Health

Medicines Development for Global Health (MDGH) is a not-for-profit pharmaceutical company based in Southbank, Victoria, dedicated to developing new and improved medicines for neglected diseases that disproportionately affect disadvantaged communities worldwide. Through innovative collaboration and resource-efficient practices, MDGH aims to elevate the health status of populations in low and middle-income countries suffering from conditions such as tuberculosis, river blindness, and scabies.

Since its inception, MDGH has made significant strides in addressing global health inequities, achieving milestones such as FDA approval for moxidectin, the first new treatment for river blindness in two decades. Their unique approach integrates necessary expertise throughout the drug development pathway to ensure effective delivery of treatments that meet vital medical needs.

Generated from the website